Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Non-Current Assets (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Non-Current Assets for 15 consecutive years, with $589000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 63.14% to $589000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $3.7 million, a 46.4% decrease, with the full-year FY2024 number at $1.5 million, down 20.85% from a year prior.
  • Non-Current Assets was $589000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $796000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $12.3 million in Q1 2022 to a low of $589000.0 in Q3 2025.
  • A 5-year average of $4.2 million and a median of $1.8 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: skyrocketed 1485.31% in 2022, then crashed 65.55% in 2024.
  • NovaBay Pharmaceuticals' Non-Current Assets stood at $10.8 million in 2021, then tumbled by 53.12% to $5.1 million in 2022, then crashed by 62.9% to $1.9 million in 2023, then decreased by 20.85% to $1.5 million in 2024, then tumbled by 60.42% to $589000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Non-Current Assets are $589000.0 (Q3 2025), $796000.0 (Q2 2025), and $834000.0 (Q1 2025).